Cost–Utility Analysis of Dupilumab for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Italy

The objective of this analysis was to estimate the incremental cost–utility ratio (ICUR) of dupilumab as an add-on treatment to best supportive care (BSC), versus BSC alone, in Italy for severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP). A simulation of outcomes and costs was und...

Descripción completa

Detalles Bibliográficos
Autores principales: De Corso, Eugenio, Furneri, Gianluca, Salsi, Daria, Fanelli, Francesca, Ronci, Gianluca, Sala, Giovanna, Bitonti, Rossella, Cuda, Domenico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225649/
https://www.ncbi.nlm.nih.gov/pubmed/35743736
http://dx.doi.org/10.3390/jpm12060951

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225649/
https://www.ncbi.nlm.nih.gov/pubmed/35743736
http://dx.doi.org/10.3390/jpm12060951

Ejemplares similares